HistoSonics

HistoSonics is a private, clinical-stage medical device company pioneering the therapeutic application of histotripsy for non-invasive tumor ablation. Its lead platform, the Edison System, is designed for the treatment of liver tumors and is supported by ongoing clinical trials like #HOPE4KIDNEY and GANNON. The company has secured significant financing, completed key trial enrollment, and obtained initial insurance coverage, positioning it to advance towards regulatory approval and commercialization in the growing interventional oncology market.

Histotripsy: a non-invasive, non-thermal, mechanical focused ultrasound platform that uses controlled acoustic cavitation ('bubble clouds') to destroy targeted tissue at a sub-cellular level. Integrated with robotic assistance and real-time ultrasound imaging in the Edison System.

HistoSonics competes in the tumor ablation market against established thermal ablation technologies like radiofrequency ablation (RFA) and microwave ablation (MWA), as well as other focused ultrasound systems (primarily thermal HIFU). Its key differentiation is the purely mechanical, non-thermal mechanism of histotripsy, which may allow for sharper treatment margins and treatment of tumors near critical structures.